Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Benjamin Chastek, Laura K. Becker, Chieh-I Chen, Puneet Mahajan & Jeffrey R. Curtis. (2017) Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. Journal of Medical Economics 20:5, pages 464-473.
Read now
Read now
Machaon MK Bonafede, Jeffrey R Curtis, Donna McMorrow, Puneet Mahajan & Chieh-I Chen. (2016) Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication. ClinicoEconomics and Outcomes Research 8, pages 707-715.
Read now
Read now
K Chatzidionysiou. (2016) Optimizing biological treatments for rheumatoid arthritis. Scandinavian Journal of Rheumatology 45:sup128, pages 64-75.
Read now
Read now
Articles from other publishers (35)
Jeffrey A. Sparks, Leslie R. Harrold, Teresa A. Simon, Keith Wittstock, Sheila Kelly, Karissa Lozenski, Vadim Khaychuk & Kaleb Michaud. (2023) Comparative effectiveness of treatments for rheumatoid arthritis in clinical practice: A systematic review. Seminars in Arthritis and Rheumatism 62, pages 152249.
Crossref
Crossref
György Nagy, Nadia M T Roodenrijs, Paco M J Welsing, Melinda Kedves, Attila Hamar, Marlies C van der Goes, Alison Kent, Margot Bakkers, Polina Pchelnikova, Etienne Blaas, Ladislav Senolt, Zoltan Szekanecz, Ernest H Choy, Maxime Dougados, Johannes WG Jacobs, Rinie Geenen, Johannes WJ Bijlsma, Angela Zink, Daniel Aletaha, Leonard Schoneveld, Piet van Riel, Sophie Dumas, Yeliz Prior, Elena Nikiphorou, Gianfranco Ferraccioli, Georg Schett, Kimme L Hyrich, Ulf Mueller-Ladner, Maya H Buch, Iain B McInnes, Désirée van der Heijde & Jacob M van Laar. (2022) EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases 81:1, pages 20-33.
Crossref
Crossref
Keerthi Talari, Vinod Ravindran, Pradip Kumar, Pravin Patil, SarathChandra Mouli, Syamasis Bandyopadhyay, BalebailG Dharmanand, Abhrajit Ray, Shankaralingam Rajeshwari, SanjivN Amin, Jyotsna Oak, Ved Chaturvedi, AnandN Malaviya & Sukumar Mukherjee. (2021) Expert Panel consensus statements on the optimal usage of rituximab for the management of rheumatoid arthritis in India. Indian Journal of Rheumatology 16:3, pages 311.
Crossref
Crossref
Nadia M T Roodenrijs, Attila Hamar, Melinda Kedves, György Nagy, Jacob M van Laar, Désirée van der Heijde & Paco M J Welsing. (2021) Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open 7:1, pages e001512.
Crossref
Crossref
Peter Youssef, Bruno Marcal, Peter Button, Matt Truman, Paul Bird, Hedley Griffiths, Lynden Roberts, Kathleen Tymms & Geoff Littlejohn. (2020) Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset. The Journal of Rheumatology 47:8, pages 1174-1181.
Crossref
Crossref
Aliza R. Karpes Matusevich, María E. Suarez‐Almazor, Scott B. Cantor, Lincy S. Lal, J. Michael Swint & Maria A. Lopez‐Olivo. (2020) Systematic Review of Economic Evaluations of Cycling Versus Swapping Medications in Patients With Rheumatoid Arthritis After Failure to Respond to Tumor Necrosis Factor Inhibitors. Arthritis Care & Research 72:3, pages 343-352.
Crossref
Crossref
Sultan M. Almogairen. (2019) Abatacept induced granulomatous hepatitis with a sarcoidosis- like reaction: a blinded trial in mice. BMC Pharmacology and Toxicology 20:1.
Crossref
Crossref
Noemi MuszbekClare Proudfoot, Marie FournierChieh-I ChenAndreas KuznikZsofia KissPeter Gal & Kaleb Michaud. (2019) Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Journal of Managed Care & Specialty Pharmacy 25:11, pages 1268-1280.
Crossref
Crossref
Martin Soubrier, Bruno Pereira, Thomas Frayssac, Angelique Fan, Marion Couderc, Sandrine Malochet‐Guinamand, Sylvain Mathieu, Zuzana Tatar, Anne Tournadre & Jean‐Jacques Dubost. (2017) Retention rates of adalimumab, etanercept and infliximab as first‐line biotherapy agent for rheumatoid arthritis patients in daily practice ‐ Auvergne experience. International Journal of Rheumatic Diseases 21:11, pages 1924-1932.
Crossref
Crossref
Monica Todoerti, Ennio Giulio Favalli, Florenzo Iannone, Ignazio Olivieri, Maurizio Benucci, Alberto Cauli, Alessandro Mathieu, Leonardo Santo, Giovanni Minisola, Giovanni Lapadula, Romano Bucci, Elisa Gremese & Roberto Caporali. (2018) Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. Rheumatology 57:Supplement_7, pages vii42-vii53.
Crossref
Crossref
Patrick Durez. (2018) Switching of biologics in RA patients who do not respond to the first biologic. Joint Bone Spine 85:4, pages 395-397.
Crossref
Crossref
Patrick Durez. (2018) Rotation des biothérapies en cas de réponse inadéquate à un premier agent biologique dans la polyarthrite rhumatoïde. Revue du Rhumatisme Monographies 85:1, pages 15-18.
Crossref
Crossref
Ennio Giulio Favalli, Maria Gabriella Raimondo, Andrea Becciolini, Chiara Crotti, Martina Biggioggero & Roberto Caporali. (2017) The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. Autoimmunity Reviews 16:12, pages 1185-1195.
Crossref
Crossref
Benjamin Chastek, Chieh-I Chen, Clare Proudfoot, Shraddha Shinde, Andreas Kuznik & Wenhui Wei. (2017) Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA. Advances in Therapy 34:11, pages 2422-2435.
Crossref
Crossref
Fabrizio Cantini, Laura Niccoli, Carlotta Nannini, Emanuele Cassarà, Olga Kaloudi, Ennio Giulio Favalli, Andrea Becciolini, Maurizio Benucci, Francesca Li Gobbi, Serena Guiducci, Rosario Foti, Marta Mosca & Delia Goletti. (2017) Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Seminars in Arthritis and Rheumatism 47:2, pages 183-192.
Crossref
Crossref
Worawit Louthrenoo, Nuntana Kasitanon, Wanruchada Katchamart, Duangkamol Aiewruengsurat, Parawee Chevaisrakul, Praveena Chiowchanwisawakit, Pornchai Dechanuwong, Punchong Hanvivadhanakul, Ajanee Mahakkanukrauh, Siriporn Manavathongchai, Chayawee Muangchan, Pongthorn Narongroeknawin, Veerapong Phumethum, Boonjing Siripaitoon, Anawat Suesuwan, Siraphop Suwannaroj, Parichat Uea-Areewongsa, Sittichai Ukritchon, Paijit Asavatanabodee, Ajchara Koolvisoot, Ratanavadee Nanagara, Kitti Totemchokchyakarn, Kanokrut Nuntirooj & Tasanee Kitumnuaypong. (2017) 2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases 20:9, pages 1166-1184.
Crossref
Crossref
Nanxin Li, Keith A. Betts, Andrew J. Messali, Martha Skup & Vishvas Garg. (2017) Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany. Clinical Therapeutics 39:8, pages 1618-1627.
Crossref
Crossref
Wenhui Wei, Keith Knapp, Li Wang, Chieh-I Chen, Gary L. Craig, Karen Ferguson & Sergio Schwartzman. (2017) Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy. Advances in Therapy 34:8, pages 1936-1952.
Crossref
Crossref
Natalia Mena-Vázquez, Sara Manrique-Arija, Inmaculada Ureña-Garnica, Carmen M. Romero-Barco, Francisco G. Jiménez-Núñez, Virginia Coret, María Victoria Irigoyen-Oyarzábal & Antonio Fernández-Nebro. (2016) Eficiency of Different Doses of Rituximab in Rheumatoid Arthritis. Reumatología Clínica (English Edition) 12:3, pages 139-145.
Crossref
Crossref
Natalia Mena-Vázquez, Sara Manrique-Arija, Inmaculada Ureña-Garnica, Carmen M. Romero-Barco, Francisco G. Jiménez-Núñez, Virginia Coret, María Victoria Irigoyen-Oyarzábal & Antonio Fernández-Nebro. (2016) Eficiencia de diferentes dosis de rituximab en la artritis reumatoide. Reumatología Clínica 12:3, pages 139-145.
Crossref
Crossref
Diana S. Novikova, Tatiana V. Popkova, Galina V. Lukina, Elena L. Luchikhina, Dmitry E. Karateev, Alexander V. Volkov, Alexander A. Novikov, Elena N. Aleksandrova & Evgeny L. Nasonov. (2016) The Effects of Rituximab on Lipids, Arterial Stiffness and Carotid Intima-Media Thickness in Rheumatoid Arthritis. Journal of Korean Medical Science 31:2, pages 202.
Crossref
Crossref
Jasvinder A. Singh, Kenneth G. Saag, S. Louis BridgesJr.Jr., Elie A. Akl, Raveendhara R. Bannuru, Matthew C. Sullivan, Elizaveta Vaysbrot, Christine McNaughton, Mikala Osani, Robert H. Shmerling, Jeffrey R. Curtis, Daniel E. Furst, Deborah Parks, Arthur Kavanaugh, James O'Dell, Charles King, Amye Leong, Eric L. Matteson, John T. Schousboe, Barbara Drevlow, Seth Ginsberg, James Grober, E. William St.Clair, Elizabeth Tindall, Amy S. Miller & Timothy McAlindon. (2016) 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & Rheumatology 68:1, pages 1-26.
Crossref
Crossref
Jasvinder A. Singh, Kenneth G. Saag, S. Louis BridgesJr.Jr., Elie A. Akl, Raveendhara R. Bannuru, Matthew C. Sullivan, Elizaveta Vaysbrot, Christine McNaughton, Mikala Osani, Robert H. Shmerling, Jeffrey R. Curtis, Daniel E. Furst, Deborah Parks, Arthur Kavanaugh, James O'Dell, Charles King, Amye Leong, Eric L. Matteson, John T. Schousboe, Barbara Drevlow, Seth Ginsberg, James Grober, E. William St.Clair, Elizabeth Tindall, Amy S. Miller & Timothy McAlindon. (2016) 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research 68:1, pages 1-25.
Crossref
Crossref
Marc D. Cohen & Edward Keystone. (2015) Rituximab for Rheumatoid Arthritis. Rheumatology and Therapy 2:2, pages 99-111.
Crossref
Crossref
Alejandro Souto, José Ramón Maneiro & Juan J. Gómez-Reino. (2015) Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology, pages kev374.
Crossref
Crossref
Ziga Rotar, Alojzija Hočevar, Anamarija Rebolj Kodre, Sonja Praprotnik & Matija Tomšič. (2015) Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry. Clinical Rheumatology 34:10, pages 1787-1793.
Crossref
Crossref
Takeo Isozaki, Sho Ishii, Shinichiro Nishimi, Airi Nishimi, Nao Oguro, Shinya Seki, Yoko Miura, Yusuke Miwa, Koei Oh, Yoichiro Toyoshima, Masanori Nakamura, Katsunori Inagaki & Tsuyoshi Kasama. (2015) A disintegrin and metalloprotease-10 is correlated with disease activity and mediates monocyte migration and adhesion in rheumatoid arthritis. Translational Research 166:3, pages 244-253.
Crossref
Crossref
Katerina Chatzidionysiou, Johan Askling, Jonas Eriksson, Lars Erik Kristensen & Ronald van Vollenhoven. (2015) Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Annals of the Rheumatic Diseases 74:5, pages 890-896.
Crossref
Crossref
Stefan Siebert, Alexander Tsoukas, Jamie Robertson & Iain McInnes. (2015) Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases. Pharmacological Reviews 67:2, pages 280-309.
Crossref
Crossref
Maria Angeles Lopez-Olivo, Matxalen Amezaga Urruela, Lynda McGahan, Eduardo N Pollono & Maria E Suarez-Almazor. (2015) Rituximab for rheumatoid arthritis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Jéssica Barreto dos Santos. (2015) What is the best biological treatment for rheumatoid arthritis? A systematic review of effectiveness. World Journal of Rheumatology 5:2, pages 108.
Crossref
Crossref
Lucia Silva-Fernandez & Kimme Hyrich. (2014) When TNF inhibitors fail in RA—weighing up the options. Nature Reviews Rheumatology 10:5, pages 262-264.
Crossref
Crossref
Hye-Lin Kim, Min-Young Lee, Sun-Young Park, Sun-Kyeong Park, Ji-Hye Byun, Sunhong Kwon & Eui-Kyung Lee. (2014) Comparative effectiveness of cycling of tumor necrosis factor-α (TNF-α) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-α inhibitor using a Bayesian approach. Archives of Pharmacal Research 37:5, pages 662-670.
Crossref
Crossref
Vincenzo Bruzzese, Cinzia Marrese, Cesare Hassan, Alessandro Andriani & Angelo Zullo. (2013) Prompt efficacy of very low-dose rituximab on monoclonal B lymphocytosis in a rheumatoid arthritis patient. International Journal of Rheumatic Diseases 16:6, pages 764-765.
Crossref
Crossref
Marc Cohen, Mohammed A Omair & Edward C Keystone. (2013) Monoclonal antibodies in rheumatoid arthritis. International Journal of Clinical Rheumatology 8:5, pages 541-556.
Crossref
Crossref